Highlights

  • 4DMedical's recent history is one of accumulating regulatory and commercial groundwork in its priority markets.
  • 4DMedical remains firmly in Investment mode.
  • The nearest catalyst is the preliminary FY26 report due in late August, which will reveal the year's Revenue trajectory, cash position and any commentary on the.
  • Cash burn is the defining risk: 4DMedical loses money, and if revenue does not scale quickly the company could return to the market for capital, diluting.

4DMedical's recent history is one of accumulating regulatory and commercial groundwork in its priority markets. Around late 2025 and early 2026 the company secured US Food and Drug Administration 510(k) clearance for its CT:VQ product — which it describes as a first-and-only CT-based ventilation-perfusion technology — with Medicare reimbursement confirmed, an important step toward US adoption. In March 2026 it received CE Mark approval for CT:VQ, enabling commercial launch across the European Union, and raised about A$83 million through a private Placement to fund its growth plans.

Latest company developments

4DMedical's recent history is one of accumulating regulatory and commercial groundwork in its priority markets. Around late 2025 and early 2026 the company secured US Food and Drug Administration 510(k) clearance for its CT:VQ product — which it describes as a first-and-only CT-based ventilation-perfusion technology — with Medicare reimbursement confirmed, an important step toward US adoption. In March 2026 it received CE Mark approval for CT:VQ, enabling commercial launch across the European Union, and raised about A$83 million through a private placement to fund its growth plans. In June 2026 the company issued an investor update flagging the launch of a clinical study branded CLEAR and an expansion of its contract with US imaging network SimonMed, deepening its American commercial footprint. The combination of regulatory clearances, reimbursement, a large Capital top-up and expanding US distribution frames the FY26 result investors are about to receive.

Financial and operating picture

4DMedical remains firmly in investment mode. Reported revenue is modest — in the order of a few million dollars, growing off a low base as scan volumes and contracts build — while the company runs meaningful operating losses typical of a MedTech commercialising novel technology across multiple regulatory jurisdictions. The A$83 million placement in March 2026 was significant precisely because cash is the critical variable for a Business at this stage: it funds the sales, clinical and regulatory effort required to turn clearances into recurring revenue. The investment case turns on the pace at which US Medicare reimbursement and contracts such as the SimonMed expansion translate into scan-based income, and whether that ramp can outrun the burn. Until revenue scales materially, conventional Earnings and Margin metrics are of limited use; the balance-sheet runway and the revenue trajectory are what matter.

What to watch next

The nearest catalyst is the preliminary FY26 report due in late August, which will reveal the year's revenue trajectory, cash position and any commentary on the US and European rollouts. Beyond that, evidence that CT:VQ adoption is accelerating under Medicare reimbursement, growth in scan volumes through networks such as SimonMed, and further contract wins or health-system partnerships would each support the thesis. Progress and read-outs from the CLEAR study could bolster the clinical case. Commercial traction in Europe following CE Mark approval offers a second geography. For a stock that has fallen a long way, tangible proof of a steepening revenue curve is the clearest route to rebuilding confidence.

Risks

Cash burn is the defining risk: 4DMedical loses money, and if revenue does not scale quickly the company could return to the market for capital, diluting existing holders despite the March 2026 raise. Adoption of a novel imaging modality depends on clinician behaviour, reimbursement Economics and integration into existing radiology workflows, all of which can be slow. Regulatory clearances do not guarantee commercial uptake. The shares are volatile and sentiment-driven, so results that miss expectations or a cautious outlook could trigger a sharp reaction, as the pre-results drift suggests. Competition from established imaging and diagnostics players is a persistent threat, and reliance on a small number of large contracts concentrates commercial risk.

Outlook

4DMedical offers a high-risk, high-potential exposure to next-generation lung imaging, backed in 2026 by FDA clearance with Medicare reimbursement, CE Mark approval, a sizeable capital raise and an expanding US contract base. The upside case is that these building blocks finally convert into a rapidly scaling, Recurring Revenue stream. The downside case is that revenue is still small, losses are ongoing, and the market has grown impatient, marking the shares well down and leaving them vulnerable around results.